Observational studyBMC cancer2026
Demographic and regional trends in Nonmelanoma skin cancer mortality in the United States, 1999-2020.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonmelanoma skin cancer (NMSC) is the most common malignancy worldwide, yet the United States lacks a dedicated registry to monitor its mortality. We aimed to characterize temporal trends and demographic and regional disparities in age-adjusted NMSC mortality in the U.S. from 1999 to 2020.
methodsWe conducted a retrospective analysis of CDC WONDER (Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research) database from 1999 to 2020 for NMSC. Age-adjusted mortality rates (AAMRs) per 100,000 persons and annual percent change (APC) were calculated and stratified by year, sex, race, age group, and geographic region.
resultsA total of 68,223 NMSC-related deaths occurred. Overall AAMR increased from 0.845 (95% CI 0.810–0.879) in 1999 to 1.002 (0.971–1.032) in 2020. Trends showed an initial decline (1999–2004 APC − 0.7%), followed by a rise (2004–2020 APC 1.6%). Men had higher mortality than women (1.55 vs. 0.43 per 100,000), with significant increases in both sexes (men 1999–2016 APC 1.4%; women 2011–2020 APC 2.5%). NH White individuals exhibited the highest AAMR (1.03) and steepest rise (2005–2015 APC 2.8%), while NH Blacks declined (APC − 1.5%) and Hispanics increased modestly (APC 0.9%). Those ≥ 65 years had the highest AAMR (5.63). Regionally, the South (1.01) and rural areas (1.04) bore the greatest burden, with persistent increases (rural APC 1.7%; suburban APC 1.4%).
conclusionsDespite diagnostic and therapeutic advances, U.S. NMSC mortality has risen, with marked demographic and geographic disparities. Enhanced mortality surveillance, targeted prevention efforts, and equitable access to dermatologic care are needed to mitigate this growing public health burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.